|Bid||7.65 x 1100|
|Ask||8.82 x 1000|
|Day's Range||7.59 - 8.25|
|52 Week Range||6.74 - 19.90|
|Beta (5Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.29|
Before we begin, I would like to read the following regarding forward-looking statements. During the course of this conference call, the company may make projections or other forward-looking statements regarding future events or future business outlook, our development efforts and their outcome, our discovery platform, anticipated progress and timeline for our programs, financial and accounting related matters as well as statements regarding our cash position. The company undertakes no obligation to update projections or forward-looking statements in the future.
What happened Shares of Compugen (NASDAQ: CGEN) were jumping 7.9% as of 11:03 a.m. EDT on Thursday. The solid gain came after the drugmaker provided its first-quarter update before the market opened. So what Today's solid uptick for the biotech stock likely had little to do with Compugen's Q1 financial results.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2021.